Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes

Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the dev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2015-01, Vol.136 (2), p.340-349
Hauptverfasser: Lee, Chien‐Hung, Peng, Chiung‐Yu, Li, Ruei‐Nian, Chen, Yu‐Chieh, Tsai, Hsiu‐Ting, Hung, Yu‐Hsiu, Chan, Te‐Fu, Huang, Hsiao‐Ling, Lai, Tai‐Cheng, Wu, Ming‐Tsang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 349
container_issue 2
container_start_page 340
container_title International journal of cancer
container_volume 136
creator Lee, Chien‐Hung
Peng, Chiung‐Yu
Li, Ruei‐Nian
Chen, Yu‐Chieh
Tsai, Hsiu‐Ting
Hung, Yu‐Hsiu
Chan, Te‐Fu
Huang, Hsiao‐Ling
Lai, Tai‐Cheng
Wu, Ming‐Tsang
description Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.
doi_str_mv 10.1002/ijc.28982
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1619314729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1619314729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</originalsourceid><addsrcrecordid>eNpdkc1uEzEQxy1ERUPhwAsgS1y4bDPj9ca73FCANlWkSgjOK8c7pg7eD-zdoJ7gEfqMfZK6TahQTx5rfvOfjz9jbxBOEUDM3dacirIqxTM2Q6hUBgKL52yWcpApzBfH7GWMWwDEAuQLdixkKbEqqxn789XFn5x22k96dH3HbR_4eEW8oR35fmipG3lvuaGwc0Z77roxaBpcYrxL_476wevo9Af-6b8S3TU8ibpmr5oUQmp0-_cmmj647geP5opaiq_YkdU-0uvDe8K-f_n8bXmerS_PVsuP68xIIUVmGgBZmE2BuiBUtrR5g9KC1WIDWisplBULaqQQRAJyo3LVWDBYAShLNj9h7_e6Q-h_TRTHunXRkPc6LTDFGhdY5SiVqBL67gm67afQpenuKVXlSiIk6u2BmjYtNfUQXKvDdf3vtAmY74HfztP1Yx6hvvesTp7VD57Vq4vlQ5DfAeQUi80</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1617937410</pqid></control><display><type>article</type><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</creator><creatorcontrib>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</creatorcontrib><description>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.28982</identifier><identifier>PMID: 24841989</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Cancer ; Case-Control Studies ; Cervical cancer ; cervical cancer screening ; cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - epidemiology ; Cervical Intraepithelial Neoplasia - pathology ; Cervical Intraepithelial Neoplasia - virology ; Cohort Studies ; DNA, Viral - genetics ; Early Detection of Cancer ; Female ; Follow-Up Studies ; Human papillomavirus ; Humans ; Medical research ; Medical screening ; Middle Aged ; Models, Statistical ; Neoplasm Staging ; Papanicolaou Test ; Papillomaviridae - genetics ; Papillomaviridae - isolation &amp; purification ; Papillomavirus Infections - complications ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - virology ; Polymerase Chain Reaction ; Prognosis ; Risk Assessment ; risk evaluation ; risk‐scoring scheme ; ROC Curve ; Taiwan - epidemiology ; Uterine Cervical Dysplasia - epidemiology ; Uterine Cervical Dysplasia - pathology ; Uterine Cervical Dysplasia - virology ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology ; Young Adult</subject><ispartof>International journal of cancer, 2015-01, Vol.136 (2), p.340-349</ispartof><rights>2014 UICC</rights><rights>2014 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.28982$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.28982$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24841989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Chien‐Hung</creatorcontrib><creatorcontrib>Peng, Chiung‐Yu</creatorcontrib><creatorcontrib>Li, Ruei‐Nian</creatorcontrib><creatorcontrib>Chen, Yu‐Chieh</creatorcontrib><creatorcontrib>Tsai, Hsiu‐Ting</creatorcontrib><creatorcontrib>Hung, Yu‐Hsiu</creatorcontrib><creatorcontrib>Chan, Te‐Fu</creatorcontrib><creatorcontrib>Huang, Hsiao‐Ling</creatorcontrib><creatorcontrib>Lai, Tai‐Cheng</creatorcontrib><creatorcontrib>Wu, Ming‐Tsang</creatorcontrib><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</description><subject>Adult</subject><subject>Aged</subject><subject>Cancer</subject><subject>Case-Control Studies</subject><subject>Cervical cancer</subject><subject>cervical cancer screening</subject><subject>cervical intraepithelial neoplasia</subject><subject>Cervical Intraepithelial Neoplasia - epidemiology</subject><subject>Cervical Intraepithelial Neoplasia - pathology</subject><subject>Cervical Intraepithelial Neoplasia - virology</subject><subject>Cohort Studies</subject><subject>DNA, Viral - genetics</subject><subject>Early Detection of Cancer</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Medical research</subject><subject>Medical screening</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Neoplasm Staging</subject><subject>Papanicolaou Test</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomaviridae - isolation &amp; purification</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - virology</subject><subject>Polymerase Chain Reaction</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>risk evaluation</subject><subject>risk‐scoring scheme</subject><subject>ROC Curve</subject><subject>Taiwan - epidemiology</subject><subject>Uterine Cervical Dysplasia - epidemiology</subject><subject>Uterine Cervical Dysplasia - pathology</subject><subject>Uterine Cervical Dysplasia - virology</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - virology</subject><subject>Young Adult</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1uEzEQxy1ERUPhwAsgS1y4bDPj9ca73FCANlWkSgjOK8c7pg7eD-zdoJ7gEfqMfZK6TahQTx5rfvOfjz9jbxBOEUDM3dacirIqxTM2Q6hUBgKL52yWcpApzBfH7GWMWwDEAuQLdixkKbEqqxn789XFn5x22k96dH3HbR_4eEW8oR35fmipG3lvuaGwc0Z77roxaBpcYrxL_476wevo9Af-6b8S3TU8ibpmr5oUQmp0-_cmmj647geP5opaiq_YkdU-0uvDe8K-f_n8bXmerS_PVsuP68xIIUVmGgBZmE2BuiBUtrR5g9KC1WIDWisplBULaqQQRAJyo3LVWDBYAShLNj9h7_e6Q-h_TRTHunXRkPc6LTDFGhdY5SiVqBL67gm67afQpenuKVXlSiIk6u2BmjYtNfUQXKvDdf3vtAmY74HfztP1Yx6hvvesTp7VD57Vq4vlQ5DfAeQUi80</recordid><startdate>20150115</startdate><enddate>20150115</enddate><creator>Lee, Chien‐Hung</creator><creator>Peng, Chiung‐Yu</creator><creator>Li, Ruei‐Nian</creator><creator>Chen, Yu‐Chieh</creator><creator>Tsai, Hsiu‐Ting</creator><creator>Hung, Yu‐Hsiu</creator><creator>Chan, Te‐Fu</creator><creator>Huang, Hsiao‐Ling</creator><creator>Lai, Tai‐Cheng</creator><creator>Wu, Ming‐Tsang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150115</creationdate><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><author>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cancer</topic><topic>Case-Control Studies</topic><topic>Cervical cancer</topic><topic>cervical cancer screening</topic><topic>cervical intraepithelial neoplasia</topic><topic>Cervical Intraepithelial Neoplasia - epidemiology</topic><topic>Cervical Intraepithelial Neoplasia - pathology</topic><topic>Cervical Intraepithelial Neoplasia - virology</topic><topic>Cohort Studies</topic><topic>DNA, Viral - genetics</topic><topic>Early Detection of Cancer</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Medical research</topic><topic>Medical screening</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Neoplasm Staging</topic><topic>Papanicolaou Test</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomaviridae - isolation &amp; purification</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - virology</topic><topic>Polymerase Chain Reaction</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>risk evaluation</topic><topic>risk‐scoring scheme</topic><topic>ROC Curve</topic><topic>Taiwan - epidemiology</topic><topic>Uterine Cervical Dysplasia - epidemiology</topic><topic>Uterine Cervical Dysplasia - pathology</topic><topic>Uterine Cervical Dysplasia - virology</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - virology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Chien‐Hung</creatorcontrib><creatorcontrib>Peng, Chiung‐Yu</creatorcontrib><creatorcontrib>Li, Ruei‐Nian</creatorcontrib><creatorcontrib>Chen, Yu‐Chieh</creatorcontrib><creatorcontrib>Tsai, Hsiu‐Ting</creatorcontrib><creatorcontrib>Hung, Yu‐Hsiu</creatorcontrib><creatorcontrib>Chan, Te‐Fu</creatorcontrib><creatorcontrib>Huang, Hsiao‐Ling</creatorcontrib><creatorcontrib>Lai, Tai‐Cheng</creatorcontrib><creatorcontrib>Wu, Ming‐Tsang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Chien‐Hung</au><au>Peng, Chiung‐Yu</au><au>Li, Ruei‐Nian</au><au>Chen, Yu‐Chieh</au><au>Tsai, Hsiu‐Ting</au><au>Hung, Yu‐Hsiu</au><au>Chan, Te‐Fu</au><au>Huang, Hsiao‐Ling</au><au>Lai, Tai‐Cheng</au><au>Wu, Ming‐Tsang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2015-01-15</date><risdate>2015</risdate><volume>136</volume><issue>2</issue><spage>340</spage><epage>349</epage><pages>340-349</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>24841989</pmid><doi>10.1002/ijc.28982</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2015-01, Vol.136 (2), p.340-349
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_1619314729
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aged
Cancer
Case-Control Studies
Cervical cancer
cervical cancer screening
cervical intraepithelial neoplasia
Cervical Intraepithelial Neoplasia - epidemiology
Cervical Intraepithelial Neoplasia - pathology
Cervical Intraepithelial Neoplasia - virology
Cohort Studies
DNA, Viral - genetics
Early Detection of Cancer
Female
Follow-Up Studies
Human papillomavirus
Humans
Medical research
Medical screening
Middle Aged
Models, Statistical
Neoplasm Staging
Papanicolaou Test
Papillomaviridae - genetics
Papillomaviridae - isolation & purification
Papillomavirus Infections - complications
Papillomavirus Infections - epidemiology
Papillomavirus Infections - virology
Polymerase Chain Reaction
Prognosis
Risk Assessment
risk evaluation
risk‐scoring scheme
ROC Curve
Taiwan - epidemiology
Uterine Cervical Dysplasia - epidemiology
Uterine Cervical Dysplasia - pathology
Uterine Cervical Dysplasia - virology
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - virology
Young Adult
title Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A05%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20evaluation%20for%20the%20development%20of%20cervical%20intraepithelial%20neoplasia:%20Development%20and%20validation%20of%20risk%E2%80%90scoring%20schemes&rft.jtitle=International%20journal%20of%20cancer&rft.au=Lee,%20Chien%E2%80%90Hung&rft.date=2015-01-15&rft.volume=136&rft.issue=2&rft.spage=340&rft.epage=349&rft.pages=340-349&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.28982&rft_dat=%3Cproquest_pubme%3E1619314729%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1617937410&rft_id=info:pmid/24841989&rfr_iscdi=true